Valsartan And Hydrochlorothiazide
Product Images NDC 50090-1422

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Valsartan And Hydrochlorothiazide (NDC 50090-1422). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label Image (Lbl500901412)

Label Image (Lbl500901412)
FDA Label Image

Label Image (Lbl500901420)

Label Image (Lbl500901420)
FDA Label Image

Label Image (Lbl500901422)

Label Image (Lbl500901422)
FDA Label Image

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)

Figure 1: Probability Of Achieving Systolic Blood Pressure <140 Mmhg At Week 8 (Valhyctz Fig1)
This text describes a study that assesses the effectiveness of a medication in reducing systolic blood pressure in individuals with hypertension. The medication, which contains a combination of Valsartan and Hydrochlorothiazide, is evaluated at a dosage of 320 mg /25 mg. The study includes a placebo group and the results are presented in a graph, which shows the probability of achieving a systolic blood pressure of less than 140 mmHg after 8 weeks of treatment.*
FDA Label Image

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)

Figure 2: Probability Of Achieving Diastolic Blood Pressure <90 Mmhg At Week 8 (Valhyctz Fig2)
The text shows a graph (Figure 2) displaying the probability of achieving a diastolic blood pressure of less than 90 mmHg after 8 weeks. The graph includes three data points: 95, 100, and 105. Additionally, there is a baseline measurement of DBP shown to be less than 90 mmHg.*
FDA Label Image

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)

Figure 3: Probability Of Achieving Systolic Blood Pressure <130 Mmhg At Week 8 (Valhyctz Fig3)
This is a graphic representation of the probability of achieving a systolic blood pressure of less than 130 mmHg at week 8 using a combination of Valsartan and Hydrochlorothiazide medication. The medication dosage is 320 mg/25 mg of Hydrochlorothiazide. The graph also shows the baseline systolic blood pressure range of 140-180 mmHg.*
FDA Label Image

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)

Figure 4: Probability Of Achieving Diastolic Blood Pressure <80 Mmhg At Week 8 (Valhyctz Fig4)
This is a graph (Figure 4) that shows the probability of achieving a diastolic blood pressure of less than 80 mmHg after 8 weeks of treatment with Valsartan and Hydrochlorothiazide at a dosage of 320 mg and 25 mg respectively, compared to a placebo. The x-axis represents the baseline diastolic blood pressure while the y-axis represents the probability percentage. There are no readable characters to describe the text outside of the figure.*
FDA Label Image

Valsartan Chemical Structure (Valhyctz Str1)

Valsartan Chemical Structure (Valhyctz Str1)
FDA Label Image

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

Hydrochlorothiazide Chemical Structure (Valhyctz Str2)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.